SCHEMBL4474896

SCHEMBL4474896

CCOC(=O)c1cc2sccc2n1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 10/20 0.67
HSD17B10 Q99714 3/20 0.67
POLB P06746 3/20 0.67
ALDH1A1 P00352 6/20 0.65
KDM4E B2RXH2 3/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
HPGD P15428 3/20 0.65
MAPT P10636 6/20 0.64
LMNA P02545 4/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
RAB9A P51151 2/20 0.64
NPC1 O15118 1/20 0.64
ATM Q13315 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
HTT P42858 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
PKM P14618 1/20 0.56
RECQL P46063 1/20 0.56
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554396 0.84 TSHR (0.78) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL24187363 0.82 TSHR (0.71) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL14434545 0.81 TSHR (0.67) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL3766716 0.78 KDM1A (0.64) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL14976726 0.78 TSHR (1.00) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL16111046 0.78 TSHR (0.67) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL17560127 0.78 MAPT (0.69) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL17554436 0.77 KDM1A (0.52) TSHRHSD17B10POLBALDH1A1KDM4E
SCHEMBL20744413 0.76 KDM1A (0.58) TSHRHSD17B10ALDH1A1KDM4EMEN1
SCHEMBL18952163 0.76 KDM1A (0.60) TSHRHSD17B10ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3668877-B1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2024-05-01 EP disclosed
EP-3189059-B1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2023-02-22 EP disclosed
US-10980777-B2 Indole derivatives as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2021-04-20 US disclosed
US-20200289463-A1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-09-17 US disclosed
CN-110407854-B Novel tetracyclic compounds 北京加科思新药研发有限公司 2020-09-15 CN disclosed
EP-3668877-A1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2020-06-24 EP disclosed
WO-2019034774-A1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA (IEO) S.R.L. (IT) 2019-02-21 WO disclosed
US-10183952-B2 Thienopyrroles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-01-22 US disclosed
US-20170260197-A1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-09-14 US disclosed
EP-3189059-A2 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-07-12 EP disclosed
WO-2016034946-A2 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2016-03-10 WO disclosed
EP-2993175-A1 Thienopyrroles as histone demethylase inhibitors IEO - Istituto Europeo di Oncologia Srl (IT) 2016-03-09 EP disclosed
US-7524843-B2 N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics AFFINIUM PHARMACEUTICALS, INC. (CA) 2009-04-28 US disclosed
US-20080125423-A1 Fab I Inhibitors DEBIOPHARM INTERNATIONAL SA (CH) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10980777-B2 Indole derivatives as histone demethylase inhibitors KDM1B, KDM1A, INMT TSHR 1249/4885HSD17B10 747/4885POLB 1952/4885
US-20200289463-A1 INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, INMT TSHR 1249/4885HSD17B10 747/4885POLB 1952/4885
US-20080125423-A1 Fab I Inhibitors SERPINB1, TFPI, TFPI2 TSHR 3254/4885HSD17B10 917/4885POLB 568/4885
US-10183952-B2 Thienopyrroles as histone demethylase inhibitors KDM1A, KDM1B, KDM3A TSHR 1132/4885HSD17B10 408/4885POLB 2606/4885
US-20170260197-A1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS KDM1A, KDM1B, KDM3A TSHR 1132/4885HSD17B10 408/4885POLB 2606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.